Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Summary

Oculis (OCS) announced a notification concerning the vesting and settlement of restricted stock units (RSUs) previously granted to a director.

The notification identifies Arshad Khanani and records an RSU vest dated 29 November 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – OCS

+3.74%

+3.74% News Effect

On the day this news was published, OCS gained 3.74%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

What This Means

This announcement reports the vesting and settlement of RSUs previously granted to a company directo...

Analysis

This announcement reports the vesting and settlement of RSUs previously granted to a company director, a routine PDMR transaction disclosure. It comes after a period of significant activity for Oculis, including positive Phase 2 ACUITY data, an FDA-supported PIONEER registrational program, and substantial equity financings under an F-3 shelf. Investors tracking the story may focus more on future clinical milestones, execution of the PIONEER trials, and how recently raised capital and registered warrant shares are utilized or absorbed over time.

Key Figures

Registered resale shares: 494,259 shares Warrant exercisable now: 59,310 shares Warrant exercise price: $12.17 +5 more

8 metrics

Registered resale shares 494,259 shares Form F-3 warrant-related resale registration

Warrant exercisable now 59,310 shares Currently exercisable portion of warrant under Form F-3

Warrant exercise price $12.17 Exercise price for 361,011 warrant shares

Warrant exercise price $18.64 Exercise price for 133,248 warrant shares

Max cash from warrant $6,877,246.59 If warrant fully exercised for 494,259 shares

Shares outstanding 52,374,811 shares Ordinary shares outstanding as of Sept 30, 2025

Underwritten offering size 4,691,358 shares Ordinary shares offered at $20.25 per share

Registered direct sale 740,740 shares Registered direct offering at $20.25 per share

Historical Context

5 past events · Latest: Dec 03 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 03	PDMR RSU vesting	Neutral	+1.1%	Disclosure of RSU vesting and settlement for director Arshad Khanani.
Nov 28	PDMR RSU vesting	Neutral	+0.0%	Notification of RSU vesting and settlement for a company director.
Nov 25	FDA meeting update	Positive	-2.2%	Positive FDA meeting enabling PIONEER registrational program for Privosegtor.
Nov 18	Director share purchase	Positive	-0.1%	Board member purchase of ordinary shares reported in managers’ transaction notice.
Nov 12	Phase 2 trial results	Positive	+2.1%	Positive Phase 2 ACUITY trial data for Privosegtor in acute optic neuritis.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News on clinical progress and financing has tended to move the stock more than routine PDMR transaction notices, which have produced minimal price reactions. Positive clinical and development updates have sometimes seen price divergence, indicating expectations and positioning may already reflect these catalysts.

Recent Company History

Over the last few months, Oculis reported multiple PDMR transaction notices, including RSU vesting events for Arshad Khanani on November 25 and November 29, 2025, which had minimal to modest impact on the share price. In contrast, a positive FDA meeting enabling the PIONEER registrational program and earlier positive Phase 2 ACUITY data for Privosegtor produced larger price moves, including a 2.06% gain and a -2.17% decline. A director share purchase in November 2025 saw little immediate reaction.

Key Terms

rsus

1 terms

rsus financial

"the vesting and settlement of RSUs previously granted to a director"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

Attachment

• Notification of managers' transaction - Arshad Khanani - 29 November 2025 RSU vest

FAQ

What did Oculis (OCS) announce on December 3, 2025 about RSUs?

Oculis announced a notification regarding the vesting and settlement of RSUs previously granted to a director.

Who is the director named in the Oculis (OCS) managers' transaction notification?

The notification names Arshad Khanani as the director linked to the RSU vest.

When did the RSUs for Arshad Khanani vest according to the Oculis (OCS) notice?

The RSUs are recorded as vesting on 29 November 2025.

Does the Oculis (OCS) notification specify whether the RSUs were settled in cash or shares?

The notice references settlement of RSUs but does not specify whether settlement was in cash or shares.

Does the Oculis (OCS) announcement disclose the number of RSUs or the shareholder dilution impact?

No; the announcement notes the RSU vesting and settlement but does not disclose quantities or dilution metrics.